(1) Lasarte-Cia A (2) Lozano T (3) Cano D (4) Mart’n-Otal C (5) Navarro F (6) Gorraiz M (7) Casares N (8) Vivas I (9) Lasarte JJ

BioMed research international | Free PMC Article

BACKGROUND/AIM: Irreversible electroporation (IRE) showed promising results for small-size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long-term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c-di-GMP, a STING agonist, intratumorally. MATERIALS AND METHODS: Intratumoral administration of c-di-GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L). RESULTS: The combined therapy increased the number of tumor-infiltrating IFN-_/TNF-_-producing CD4 and CD8 T cells and delayed tumor growth, as compared to the effect observed in groups treated with c-di-GMP or IRE alone. CONCLUSION: These results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.

Author Info: (1) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (2) Immunology and Immunotherapy Program

Author Info: (1) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (2) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (3) Department of Radiology, Cl’nica Universidad de Navarra, Pamplona, Spain. (4) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (5) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (6) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (7) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain. (8) Department of Radiology, Cl’nica Universidad de Navarra, Pamplona, Spain. (9) Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 IDISNA, Pamplona, Spain.

Citation: Biomed Res Int 2021 2021:8852233 Epub01/27/2021

Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33575350

Tags: